Shire gets positive opinion from EMA on rare gastrointestinal disease treatment
May 27, 2016Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, Revestive, Shire, gastrointestinal, paediatric, short bowel syndrome, treatment
Shire (LSE: SHP) has announced that it has received a positive opinion from the European Medicines Agency’s (EMA) Committee for …
Roche says comparison study for its Gazyva/ Gazyvaro showed superior progression-free survival in follicular lymphoma
May 27, 2016Medical Communications, Research and Development Comparison Study, Roche, drug trial, follicular lymphoma
Roche (SIX: ROG) on Friday said late-stage comparison trials for its drug to treat a slower form of non-Hodgkin lymphoma …
AstraZeneca says NDA for drug to treat hyperkalaemia gets observations from the US FDA
May 27, 2016Medical Communications, Research and Development AstraZeneca, NDA, US FDA, regulation
UK pharma firm AstraZeneca (LSE: AZN) on Friday said the US Food and Drug Administration (FDA) has issued a complete …
FDA approves first buprenorphine implant for opioid dependence
May 27, 2016Medical Communications, Sales and Marketing FDA, addiction, buprenorphine, dependence, implant, opioid, probuphine
The US Food and Drug Administration (FDA) has approved Probuphine, which is the first buprenorphine implant for the maintenance treatment …
AstraZeneca says its Faslodex shows superiority in comparison study for advanced breast cancer
May 27, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, breast cancer, comparision study, drug trial
UK drugmaker AstraZeneca (LSE: AZN) on Friday said late-stage comparison trials for its drug to treat advanced breast cancer showed …
Sam Eldessouky named new corporate controller at Valeant
May 26, 2016Valeant Pharmaceuticals (NYSE: VRX) has announced that Sam Eldessouky has been named senior vice president and corporate controller. Eldessouky joins …
Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance
May 26, 2016Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer
The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat …
Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials
May 26, 2016Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelara, crohn's disease, drug trial
Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials. The company said a significant …
Shares at Sarepta Therapeutics jump after FDA delay in drug approval review
May 26, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, Sarepta Therapeutics, approval, delay, delayed announcement, muscular dystrophy, sarepta, treatment
Sarepta Therapeutics (NASDAQ: SRPT) has witnessed a sharp rise in the price of its shares after the US Food and …
US FDA committee recommends approval of Sanofi’s combination therapy for type 2 diabetes
May 26, 2016Research and Development, Sales and Marketing
French drug firm Sanofi (Euronext: SAN) said the US Food and Drug Administration (FDA) advisory committee has recommended the approval …
FDA approves CSL haemophilia A drug
May 26, 2016Sales and Marketing CSL, afstyla, haemophilia a, treatment
CSL (ASX: CSL) has announced that the US Food and Drug Administration (FDA) has approved Afstyla (antihaemophilic factor [recombinant), single …
NICE recommends Jevtana for advanced prostate cancer
May 25, 2016Sales and Marketing Jevtana, NICE, approval, prostate cancer, recommendation
The National Institute for Health and Care Excellence (NICE) has recommended Sanofi Genzyme’s Jevtana (cabazitaxel), in combination with prednisone or …
Sanofi makes move to remove Medivation board; Medivation hits back
May 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Medivation, Sanofi, removal of board, takeover
Sanofi (NYSE: SNY) has taken their proposed takeover of Medivation (NASDAQ: MDVN) up several notches, with the French company filing …
Gilead names Kevin Young new chief operating officer
May 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead
Gilead Sciences (NASDAQ: GILD) has announced two new senior appointments, including Kevin Young as its new chief operating officer. Martin …
Eli Lilly showcases emerging pipeline to investors
May 25, 2016Research and Development Eli Lilly, investors, lilly, pipeline, research and development
Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting its potential to launch 20 …
Monsanto rejects Bayer’s $62 billion offer
May 25, 2016Business Services, Research and Development, Sales and Marketing Bayer, Financial, M&A, MA, deal, monsanto
World’s largest seed maker Monsanto (NYSE: MON) has rejected the $62 billion takeover offer from Germany’s Bayer AG (ETR: BAYN) …
FDA committee unanimously recommends Novo Nordisk diabetes combo, IDegLira
May 25, 2016Research and Development, Sales and Marketing FDA, Novo Nordisk, Panel, Tresiba, Victoza, committee, ideglira, recommendation, staff
Novo Nordisk has announced that a US Food and Drug Administration (FDA) advisory committee has unanimously recommended IDegLira, a type-2 …
Nice recommends three drugs to treat diabetes
May 25, 2016Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes
The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …
Rare disease treatment advocates criticise NHS delays in commissioning
May 24, 2016Medical Communications, Sales and Marketing NHS, commissioning
Medical professionals are calling on NHS England to speed up access to treatment for patients with a rare genetic disease …
GSK says asthma drug Breo shows superior results over standard care in major study
May 24, 2016Research and Development, Sales and Marketing COPD, GSK, asthma, breo, drug trial
UK drugmaker GlaxoSmithKline (LSE: GSK) on Tuesday said inhaled medicine Breo proved significantly better than standard care in a major …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
